Researchers at U of T Engineering have developed a new way of growing realistic human tissues outside the body. Their “person-on-a-chip” technology, called AngioChip, is a powerful platform for discovering and testing new drugs, and could eventually be used to repair or replace damaged organs.
Professor Milica Radisic (IBBME, ChemE), graduate student Boyang Zhang and their collaborators are among those research groups around the world racing to find ways to grow human tissues in the lab, under conditions that mimic a real person’s body. They have developed unique methods for manufacturing small, intricate scaffolds for individual cells to grow on. These artificial environments produce cells and tissues that resemble the real thing more closely than those grown lying flat in a petri dish.
he team’s recent creations have included BiowireTM — an innovative method of growing heart cells around a silk suture — as well as a scaffold for heart cells that snaps together like sheets of Velcro™. But AngioChip takes tissue engineering to a whole new level. “It’s a fully three-dimensional structure complete with internal blood vessels,” says Radisic. “It behaves just like vasculature, and around it there is a lattice for other cells to attach and grow.” The work — which is published todayin the journal Nature Materials — was produced collaboratively with researchers from across U of T, including Professor Michael Sefton (ChemE, IBBME), Professor Aaron Wheeler (Chemistry, IBBME) and their research teams, as well as researchers from Toronto General Hospital and University Health Network.
Zhang built the scaffold out of POMaC, a polymer that is both biodegradable and biocompatible. The scaffold is built out of a series of thin layers, stamped with a pattern of channels that are each about 50 to 100 micrometres wide. The layers, which resemble the computer microchips, are then stacked into a 3D structure of synthetic blood vessels. As each layer is added, UV light is used to cross-link the polymer and bond it to the layer below.
When the structure is finished, it is bathed in a liquid containing living cells. The cells quickly attach to the inside and outside of the channels and begin growing just as they would in the human body.
“Previously, people could only do this using devices that squish the cells between sheets of silicone and glass,” says Radisic. “You needed several pumps and vacuum lines to run just one chip. Our system runs in a normal cell culture dish, and there are no pumps; we use pressure heads to perfuse media through the vasculature. The wells are open, so you can easily access the tissue.”
Using the platform, the team has built model versions of both heart and liver tissues that function like the real thing. “Our liver actually produced urea and metabolized drugs,” says Radisic. They can connect the blood vessels of the two artificial organs, thereby modelling not just the organs themselves, but the interactions between them. They’ve even injected white blood cells into the vessels and watched as they squeezed through gaps in the vessel wall to reach the tissue on the other side, just as they do in the human body.
AngioChip has great potential in the field of pharmaceutical testing. Current drug-testing methods, such as animal testing and controlled clinical trials, are costly and fraught with ethical concerns. Testing on lab-grown human tissues would provide a realistic model at a fraction of the cost, but this area of research is still in its infancy. “In the last few years, it has become possible to order cultures of human cells for testing, but they’re grown on a plate, a two-dimensional environment,” says Radisic. “They don’t capture all the functional hallmarks of a real heart muscle, for example.”
A more realistic platform like AngioChip could enable drug companies to detect dangerous side effects and interactions between organ compartments long before their products reach the market, saving countless lives. It could also be used to understand and validate the effectiveness of current drugs and even to screen libraries of chemical compounds to discover new drugs. Through TARA Biosystems Inc., a spin-off company co-founded by Radisic, the team is already working on commercializing the technology.
In future, Radisic envisions her lab-grown tissues being implanted into the body to repair organs damaged by disease. Because the cells used to seed the platform can come from anyone, the new tissues could be genetically identical to the intended host, reducing the risk of organ rejection. Even in its current form, the team has shown that the AngioChip can be implanted into a living animal, its artificial blood vessels connected to a real circulatory system. The polymer scaffolding itself simply biodegrades after several months.
The Latest on: Tissue engineering
via Google News
The Latest on: Tissue engineering
- Using Microparticles to Measure Oxygen in Tissueson July 26, 2019 at 9:25 am
The field of tissue engineering is rapidly progressing, in large part thanks to hydrogel scaffolds that provide a comfortable home for new cells. A major issue that researchers bump against is ... […]
- Biomaterials Market Growth to Achieve 12% CAGR through 2023 with Highest Potential to Growth, Says MRFRon July 26, 2019 at 4:38 am
Biomaterials are materials that have either natural or synthetic origin and used in advanced medical technologies for tissue engineering, plastic surgery, and more. The technology is the choicest ... […]
- The NASA BioFabrication Facility Launches Today: Will Use Microgravity to Grow Heart Tissue in Spaceon July 23, 2019 at 9:23 pm
so if you are doing tissue engineering experiments and want to try them out in space, welcome your new BFF!” said Church. The BFF is taking a one-way trip to space for quite a while. The first ... […]
- Genipin and EDC crosslinking of extracellular matrix hydrogel derived from human umbilical cord for neural tissue repairon July 23, 2019 at 2:23 am
One of these strategies – the tissue engineering approach - is bridging the lesion with the use of a biomimetic scaffold which is able to fill the lesion cavity and provide the necessary ... […]
- Cell Therapy and Tissue Engineering 2019 Market Segmentation,Application,Technology & Market Analysis Research Report to 2024on July 22, 2019 at 7:28 am
Cell therapy is the use of living cells to treat or potentially cure a human disease or injury. Tissue Engineering (TE) is a medical field that focuses on restoring, maintaining, improving, or ... […]
- Soft tissue repair Market is expected to reach $25,635 million by 2025 at a CAGR of 5.6%on July 18, 2019 at 6:13 am
Moreover, the launch of novel techniques in tissue engineering is expected to create lucrative opportunities in the market. The global soft tissue repair market was valued at $16,554 million in 2017, ... […]
- FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering Online Seminaron July 16, 2019 at 11:56 am
DUBLIN, July 16, 2019 /PRNewswire/ -- The "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering" training has been added to ResearchAndMarkets.com's ... […]
- Online Seminar: FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering (July 18-19, 2019) - ResearchAndMon July 16, 2019 at 5:39 am
DUBLIN--(BUSINESS WIRE)--The "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering" training has been added to ResearchAndMarkets.com's offering. This ... […]
- Tissue engineering market Comprehensive Analysis, Growth Forecast from 2018 to 2025on July 15, 2019 at 11:56 pm
growth over the next seven years. Rising need to bridge the organ demand and supply gap is expected to drive industry demand. Orthopedic applications ... […]
- Tissue Engineering, Part C (image)on July 15, 2019 at 8:31 am
Tissue Engineering is an authoritative peer-reviewed journal published monthly online and in print in three parts: Part A, the flagship journal published 24 times per year; Part B: Reviews, published ... […]
via Bing News